» Articles » PMID: 21122980

Pyramidal and Extrapyramidal Scale (PEPS): a New Scale for the Assessment of Motor Impairment in Vascular Cognitive Impairment Associated with Small Vessel Disease

Overview
Publisher Elsevier
Specialty Neurology
Date 2010 Dec 3
PMID 21122980
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Vascular cognitive impairment associated with small vessel disease (sVCI) may manifest as both cognitive and motor dysfunctions. However, few instruments exist for systematically assessing motor symptoms in sVCI, even though many neuropsychological tests exist to evaluate cognitive function. We developed a new scale for assessing motor impairments and evaluated the reliability and validity of the scale in patients with sVCI.

Methods: A new motor scale, called the PEPS (Pyramidal and Extra Pyramidal Scale for sVCI), consisted of 34 items (for 60 total points) with 5 subdomains: corticospinal, corticobulbar, extrapyramidal signs, gait abnormalities, and gait severity. The PEPS was compared between 75 patients with sVCI and 73 control patients who had dementia or mild cognitive impairment (MCI) without ischemia.

Results: The PEPS had good interrater and test-retest reliability, and it was moderately to highly correlated with the UPDRS, NIHSS, MMSE, CDR, and ADL scales. An optimal cut-off score of PEPS to discriminate dementia or MCI patients with ischemia from those without ischemia was 6.5 with a sensitivity of 88% and a specificity of 100%.

Conclusion: The PEPS is a reliable and valid scale that can be used to assess and monitor motor impairment in patients with vascular cognitive impairment due to small vessel disease.

Citing Articles

Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions.

Cho S, Choe Y, Kim Y, Kim H, Jang H, Kim Y J Alzheimers Dis. 2020; 76(1):281-290.

PMID: 32474468 PMC: 9711935. DOI: 10.3233/JAD-200079.


A Comparison Study of Cilostazol and Aspirin on Changes in Volume of Cerebral Small Vessel Disease White Matter Changes: Protocol of a Multicenter, Randomized Controlled Trial.

Han H, Kim B, Youn Y, Jeong J, Kim J, Lee J Dement Neurocogn Disord. 2020; 18(4):138-148.

PMID: 31942173 PMC: 6946612. DOI: 10.12779/dnd.2019.18.4.138.


Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study.

Kim Y, Seo S, Park S, Yang J, Lee J, Lee J Sci Rep. 2017; 7(1):1910.

PMID: 28507298 PMC: 5432504. DOI: 10.1038/s41598-017-02046-y.


The neural correlates of motor intentional disorders in patients with subcortical vascular cognitive impairment.

Kim G, Seo S, Jung K, Kwon O, Kwon H, Kim J J Neurol. 2015; 263(1):89-99.

PMID: 26514838 DOI: 10.1007/s00415-015-7946-6.


Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment.

Lee M, Seo S, Na D, Kim C, Park J, Kim G JAMA Psychiatry. 2014; 71(4):412-22.

PMID: 24554306 PMC: 5849078. DOI: 10.1001/jamapsychiatry.2013.4506.